Skip NavigationSkip to Content

Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants

  1. Author:
    Klinman, D. M.
    Klaschik, S.
    Tomaru, K.
    Shirota, H.
    Tross, D.
    Ikeuchi, H.
  2. Author Address

    [Klinman, Dennis M.; Klaschik, Sven; Tomaru, Koji; Shirota, Hidekazu; Tross, Debra; Ikeuchi, Hidekazu] NCI, Canc & Inflammat Program, Frederick, MD 21702 USA.;Klinman, DM, NCI, Canc & Inflammat Program, Bldg 567,Rm 205, Frederick, MD 21702 USA.;klinmand@mail.nih.gov
    1. Year: 2010
    2. Date: Feb
  1. Journal: Vaccine
    1. 28
    2. 8
    3. Pages: 1919-1923
  2. Type of Article: Article
  3. ISSN: 0264-410X
  1. Abstract:

    Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs mimic the immunostimulatory activity of bacterial DNA. CpG ODN directly stimulate B cells and plasmacytoid dendritic cells (pDC), promote the production of Th1 and pro-inflammatory cytokines, and trigger the maturation/activation of professional antigen presenting cells. CpG ODN are finding use as vaccine adjuvants, where they increase the speed, magnitude and duration of vaccine-specific immune responses. For example, CpG ODN significantly prolong the protection induced by AVA (Anthrax Vaccine Adsorbed). Unexpectedly, a majority of animals immunized with CpG-adjuvanted AVA maintain resistance to anthrax infection even after their Ab titers decline to sub-protective levels. This survival is mediated by the de novo production of protective Abs by high affinity long-lived memory B cells. The immunostimulatory activity of CpG ODN was probed at the molecular level by microarray. Results show that a small group of 'inducers' rapidly up-regulated a large network genes following CpG treatment of mice. This stimulatory activity is quenched by 'suppressors' that down-regulate the expression of targeted genes, including most of the 'inducers'. These findings shed light on the mechanism underlying CpG-mediated immune activation and therapeutic activity. Published by Elsevier Ltd.

    See More

External Sources

  1. DOI: 10.1016/j.vaccine.2009.10.094
  2. WOS: 000275918900005

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel